Tetrandrine inhibits Wnt/β-catenin signaling and suppresses tumor growth of human colorectal cancer

Molecular Pharmacology

Volumn 79, Issue 2, 2011, Pages 211-219

  He, Bai Cheng ^a,b   Gao, Jian Li ^a,b   Zhang, Bing Qiang ^a,b   Luo, Qing ^a   Shi, Qiong ^a,b   Kim, Stephanie H ^b   Huang, Enyi ^b,c   Gao, Yanhong ^d   Yang, Ke ^b,e   Wagner, Eric R ^b   Wang, Linyuan ^b   Tang, Ni ^a,b   Luo, Jinyong ^a,b   Liu, Xing ^a,b   Li, Mi ^a,b   Bi, Yang ^a,b   Shen, Jikun ^b   Luther, Gaurav ^b   Hu, Ning ^a,b   Zhou, Qixin ^a   Luu, Hue H ^b   Haydon, Rex C ^b   Zhao, Yingming ^f   He, Tong Chuan ^a,b   more..

^a CHONGQING MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^c CHONGQING UNIVERSITY   (China)

^d SHANGHAI JIAO TONG UNIVERSITY   (China)

^e THIRD MILITARY MEDICAL UNIVERSITY   (China)

^f UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CAMPTOTHECIN; CARBOPLATIN; DOXORUBICIN; FLUOROURACIL; LYMPHOCYTE ENHANCER FACTOR; MYC PROTEIN; PACLITAXEL; T CELL FACTOR PROTEIN; TETRANDRINE; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; VINCRISTINE; WNT PROTEIN;

ALLELE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CHINESE MEDICINE; COLORECTAL CANCER; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

ANIMALS; BENZYLISOQUINOLINES; BETA CATENIN; CELL LINE, TUMOR; CELL PROLIFERATION; COLORECTAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; SIGNAL TRANSDUCTION; TRANSPLANTATION, HETEROLOGOUS; WNT PROTEINS;

EID: 78751559362     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.110.068668     Document Type: Article

References (38)

1. Aggarwal S and Chu E (2005) Current therapies for advanced colorectal cancer. Oncology 19:589-595. (Pubitemid 350042589)
2. Chan TA, Wang Z, Dang LH, Vogelstein B, and Kinzler KW (2002) Targeted inactivation of CTNNB1 reveals unexpected effects of beta-catenin mutation. Proc Natl Acad Sci USA 99:8265-8270.
3. Chen XL, Ren KH, He HW, and Shao RG (2008) Involvement of PI3K/AKT/GSK3beta pathway in tetrandrine-induced G1 arrest and apoptosis. Cancer Biol Ther 7:1073-1078.
4. Chen Y, Chen JC, and Tseng SH (2009) Tetrandrine suppresses tumor growth and angiogenesis of gliomas in rats. Int J Cancer 124:2260-2269.
5. Cho HS, Chang SH, Chung YS, Shin JY, Park SJ, Lee ES, Hwang SK, Kwon JT, Tehrani AM, Woo M, et al. (2009) Synergistic effect of ERK inhibition on tetrandrine-induced apoptosis in A549 human lung carcinoma cells. J Vet Sci 10:23-28.
6. Cragg GM, Grothaus PG, and Newman DJ (2009) Impact of natural products on developing new anti-cancer agents. Chem Rev 109:3012-3043.
7. Haydon RC, Deyrup A, Ishikawa A, Heck R, Jiang W, Zhou L, Feng T, King D, Cheng H, Breyer B, et al. (2002a) Cytoplasmic and/or nuclear accumulation of the betacatenin protein is a frequent event in human osteosarcoma. Int J Cancer 102:338-342.
8. Haydon RC, Zhou L, Feng T, Breyer B, Cheng H, Jiang W, Ishikawa A, Peabody T, Montag A, Simon MA, et al. (2002b) Nuclear receptor agonists as potential differentiation therapy agents for human osteosarcoma. Clin Cancer Res 8:1288-1294.
9. He BC, Chen L, Zuo GW, Zhang W, Bi Y, Huang J, Wang Y, Jiang W, Luo Q, Shi Q, et al. (2010) Synergistic antitumor effect of the activated PPARgamma and retinoid receptors on human osteosarcoma. Clin Cancer Res 16:2235-2245.
10. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, Morin PJ, Vogelstein B, and Kinzler KW (1998) Identification of c-MYC as a target of the APC pathway. Science 281:1509-1512.
11. Ishiyama M, Tominaga H, Shiga M, Sasamoto K, Ohkura Y, and Ueno K (1996) A combined assay of cell viability and in vitro cytotoxicity with a highly watersoluble tetrazolium salt, neutral red and crystal violet. Biol Pharm Bull 19:1518-1520. (Pubitemid 26403266)
12. King VF, Garcia ML, Himmel D, Reuben JP, Lam YK, Pan JX, Han GQ, and Kaczorowski GJ (1988) Interaction of tetrandrine with slowly inactivating calcium channels. Characterization of calcium channel modulation by an alkaloid of Chinese medicinal herb origin. J Biol Chem 263:2238-2244.
13. Kinzler KW and Vogelstein B (1996) Lessons from hereditary colorectal cancer. Cell 87:159-170.
14. Koehn FE and Carter GT (2005) The evolving role of natural products in drug discovery. Nat Rev Drug Discov 4:206-220. (Pubitemid 40372555)
15. Lee JH, Kang GH, Kim KC, Kim KM, Park DI, Choi BT, Kang HS, Lee YT, and Choi YH (2002) Tetrandrine-induced cell cycle arrest and apoptosis in A549 human lung carcinoma cells. Int J Oncol 21:1239-1244.
16. Li X, Zhen D, Lu X, Xu H, Shao Y, Xue Q, Hu Y, Liu B, and Sun W (2010) Enhanced cytotoxicity and activation of ROS-dependent c-Jun NH2-terminal kinase and caspase-3 by low doses of tetrandrine-loaded nanoparticles in Lovo cells - a possible Trojan strategy against cancer. Eur J Pharm Biopharm 75:334-340.
17. Liu B, Wang T, Qian X, Liu G, Yu L, and Ding Y (2008) Anticancer effect of tetrandrine on primary cancer cells isolated from ascites and pleural fluids. Cancer Lett 268:166-175.
18. Luo J, Chen J, Deng ZL, Luo X, Song WX, Sharff KA, Tang N, Haydon RC, Luu HH, and He TC (2007) Wnt signaling and human diseases: what are the therapeutic implications? Lab Invest 87:97-103.
19. Luo J, Tang M, Huang J, He BC, Gao JL, Chen L, Zuo GW, Zhang W, Luo Q, Shi Q, et al. (2010) TGFbeta/BMP type I receptors ALK1 and ALK2 are essential for BMP9-induced osteogenic signaling in mesenchymal stem cells. J Biol Chem 285:29588-29598.
20. Luo Q, Kang Q, Si W, Jiang W, Park JK, Peng Y, Li X, Luu HH, Luo J, Montag AG, et al. (2004) Connective tissue growth factor (CTGF) is regulated by Wnt and bone morphogenetic proteins signaling in osteoblast differentiation of mesenchymal stem cells. J Biol Chem 279:55958-55968.
21. Luo X, Chen J, Song WX, Tang N, Luo J, Deng ZL, Sharff KA, He G, Bi Y, He BC, et al. (2008a) Osteogenic BMPs promote tumor growth of human osteosarcomas that harbor differentiation defects. Lab Invest 88:1264-1277.
22. Luo X, Sharff KA, Chen J, He TC, and Luu HH (2008b) S100A6 expression and function in human osteosarcoma. Clin Orthop Relat Res 466:2060-2070.
23. Luu HH, Kang Q, Park JK, Si W, Luo Q, Jiang W, Yin H, Montag AG, Simon MA, Peabody TD, et al. (2005a) An orthotopic model of human osteosarcoma growth and spontaneous pulmonary metastasis. Clin Exp Metastasis 22:319-329.
24. Luu HH, Zhou L, Haydon RC, Deyrup AT, Montag AG, Huo D, Heck R, Heizmann CW, Peabody TD, Simon MA, et al. (2005b) Increased expression of S100A6 is associated with decreased metastasis and inhibition of cell migration and anchorage independent growth in human osteosarcoma. Cancer Lett 229:135-148.
25. Mann J (2002) Natural products in cancer chemotherapy: past, present and future. Nat Rev Cancer 2:143-148. (Pubitemid 37328801)
26. Meng LH, Zhang H, Hayward L, Takemura H, Shao RG, and Pommier Y (2004) Tetrandrine induces early G1 arrest in human colon carcinoma cells by down-regulating the activity and inducing the degradation of G1-S-specific cyclin-dependent kinases and by inducing p53 and p21Cip1. Cancer Res 64:9086-9092.
27. Ng LT, Chiang LC, Lin YT, and Lin CC (2006) Antiproliferative and apoptotic effects of tetrandrine on different human hepatoma cell lines. Am J Chin Med 34:125-135. (Pubitemid 43231407)
28. Nomura M, Yamazaki R, Takaya M, Kikuchi M, Takahashi-Nishioka T, Akiyama K, Akiyama N, Moritani S, and Kobayashi S (2007) Inhibition of tetrandrine on epidermal growth factor-induced cell transformation and its signal transduction. Anticancer Res 27:3187-3193.
29. Oh SH and Lee BH (2003) Induction of apoptosis in human hepatoblastoma cells by tetrandrine via caspase-dependent Bid cleavage and cytochrome c release. Biochem Pharmacol 66:725-731.
30. Sharff KA, Song WX, Luo X, Tang N, Luo J, Chen J, Bi Y, He BC, Huang J, Li X, et al. (2009) Hey1 basic helix-loop-helix protein plays an important role in mediating BMP9-induced osteogenic differentiation of mesenchymal progenitor cells. J Biol Chem 284:649-659.
31. Si W, Kang Q, Luu HH, Park JK, Luo Q, Song WX, Jiang W, Luo X, Li X, Yin H, et al. (2006) CCN1/Cyr61 is regulated by the canonical Wnt signal and plays an important role in Wnt3A-induced osteoblast differentiation of mesenchymal stem cells. Mol Cell Biol 26:2955-2964.
32. Su Y, Luo X, He BC, Wang Y, Chen L, Zuo GW, Liu B, Bi Y, Huang J, Zhu GH, et al. (2009) Establishment and characterization of a new highly metastatic human osteosarcoma cell line. Clin Exp Metastasis 26:599-610.
33. Tang N, Song WX, Luo J, Luo X, Chen J, Sharff KA, Bi Y, He BC, Huang JY, Zhu GH, et al. (2009) BMP-9-induced osteogenic differentiation of mesenchymal progenitors requires functional canonical Wnt/beta-catenin signalling. J Cell Mol Med 13:2448-2464.
34. Wang G, Lemos JR, and Iadecola C (2004) Herbal alkaloid tetrandrine: from an ion channel blocker to inhibitor of tumor proliferation. Trends Pharmacol Sci 25:120-123. (Pubitemid 38264500)
35. Wu JM, Chen Y, Chen JC, Lin TY, and Tseng SH (2010) Tetrandrine induces apoptosis and growth suppression of colon cancer cells in mice. Cancer Lett 287:187-195.
36. Xu WL, Shen HL, Ao ZF, Chen BA, Xia W, Gao F, and Zhang YN (2006) Combination of tetrandrine as a potential-reversing agent with daunorubicin, etoposide and cytarabine for the treatment of refractory and relapsed acute myelogenous leukemia. Leuk Res 30:407-413.
37. Zhou L, An N, Haydon RC, Zhou Q, Cheng H, Peng Y, Jiang W, Luu HH, Vanichakarn P, Szatkowski JP, et al. (2003) Tyrosine kinase inhibitor STI-571/Gleevec down-regulates the beta-catenin signaling activity. Cancer Lett 193:161-170.
38. Zhou L, An N, Jiang W, Haydon R, Cheng H, Zhou Q, Breyer B, Feng T and He TC (2002) Fluorescence-based functional assay for Wnt/beta-catenin signaling activity. Biotechniques 33:1126-1132.